These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12724006)

  • 1. Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens.
    Manfredi R; Calza L; Chiodo F
    AIDS Patient Care STDS; 2003 Mar; 17(3):105-14. PubMed ID: 12724006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
    Fitzgibbon JE; Gaur S; Walsman SM; Janahi M; Whitley-Williams P; John JF
    AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1321-8. PubMed ID: 11602042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of efavirenz as a part of late rescue antiretroviral treatment.
    Manfredi R; Rizzo E; Calza L; Chiodo F
    HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
    Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J
    HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line nevirapine in combination with nucleoside analogues compared with nevirapine added to a salvage HAART.
    Manfredi R; Chiodo F
    Infection; 2000; 28(3):167-70. PubMed ID: 10879643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
    BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers.
    Castagna A; Danise A; Giudici B; Lazzarin A; Castelli F; Paraninfo G; Carosi G; Carriero PL
    J Chemother; 2002 Apr; 14(2):189-93. PubMed ID: 12017376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
    Walter H; Schmidt B; Rascu A; Helm M; Moschik B; Paatz C; Kurowski M; Korn K; Uberla K; Harrer T
    Antivir Ther; 2000 Dec; 5(4):249-56. PubMed ID: 11142619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in durability of treatment with initial PI-based regimens.
    Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
    HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    Roca B; Gómez CJ; Arnedo A
    J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus.
    Moyle GJ; Youle M; Higgs C; Monaghan J; Prince W; Chapman S; Clendeninn N; Nelson MR
    J Clin Pharmacol; 1998 Aug; 38(8):736-43. PubMed ID: 9725550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.